SpringWorks Therapeutics financials at a glance

+ Portfolio

The revenue of SpringWorks Therapeutics is reported as 0.00545 billion Dollars in the fiscal year 2023. The earnings were -5.15 Dollars per share in 2023, which was 1.15 higher than 2022. And about -0.22347 billion Dollars are reported as free cash flow in the financials of SpringWorks Therapeutics 2023. No dividends were paid to the shareholders of the SpringWorks Therapeutics stock NasdaqGS:SWTX in the financial year 2023.

$5.45M

Revenue

$-5.15

Earnings Per Share

92.25%

Gross Margin %

$-,170.00M

Free Cash Flow

Revenue

5.45

Earnings Per Share

-5.15

Gross Margin %

92.25

Free Cash Flow

-,170.00

Financials

Year	Year	TTM	2023	2022	2021	2020	2019
Rev.	Revenue	N/A	$5.45M	$0.00M	$0.00M	$35.00M	$0.00M
GM %	Gross Margin %	0.00%	92.25%	0.00%	0.00%	100.00%	0.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	-,132.35%	0.00%
EPS	Earnings Per Share	$-4.89	$-5.15	$-5.21	$-2.79	$-0.82	$-3.61
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%
Sha.	Shares	N/AM	73.68M	62.28M	48.87M	48.29M	43M
OCF	Operating Cash Flow	N/A	$-,222.80M	$-,161.56M	$-,127.88M	$-32.19M	$-47.44M
FCF	Free Cash Flow	N/A	$-,170.00M	$-,171.76M	$-,129.89M	$-32.83M	$-48.11M
FCFS	Free Cash Flow Per Share	$-3.62	$-3.65	$-3.22	$-2.68	$-0.76	$-3.62

SpringWorks Therapeutics financials at a glance

Financials

Discover